Related Experiment Video

Updated: Jun 21, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Small molecule inhibitors of Bcl-2 function: modulators of apoptosis and promising anticancer agents

Z Huang1

  • 1Department of Biochemistry, University of Illinois, Urbana, IL 61801, USA. z-huang@uivc.edu

Current Opinion in Drug Discovery & Development
|August 4, 2009
PubMed

Insights

Researchers are developing new cancer drugs by targeting Bcl-2 proteins, which regulate programmed cell death (apoptosis). Small molecules and compounds are being studied to block these proteins, offering new therapeutic avenues for cancer treatment.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Pharmacology

Background:

  • Bcl-2 family proteins are key regulators of apoptosis, a process implicated in various human diseases.
  • Dysregulation of apoptosis is central to cancer development, making Bcl-2 proteins attractive therapeutic targets.
  • Structure-function analyses identified a critical surface pocket on anti-apoptotic proteins like Bcl-2 and Bcl-xL.

Purpose of the Study:

  • To review recent advancements in identifying compounds that inhibit the anti-apoptotic function of Bcl-2 and Bcl-xL.
  • To explore the potential of these compounds as novel anticancer therapeutics.
  • To highlight progress in understanding Bcl-2-regulated apoptosis.

Main Methods:

  • Literature review of studies on peptides, natural compounds, and synthetic molecules targeting Bcl-2 family proteins.
  • Analysis of structure-function relationships of Bcl-2 and Bcl-xL.
  • Examination of drug discovery efforts focused on small molecules that antagonize Bcl-2/Bcl-xL functions.

Main Results:

  • Recent progress has been made in discovering peptides and non-peptidic compounds (natural and synthetic) that inhibit Bcl-2 and Bcl-xL.
  • These agents effectively block the anti-apoptotic function of these proteins.
  • The identified compounds show promise in modulating cell death pathways.

Conclusions:

  • Inhibitors of Bcl-2 and Bcl-xL represent a promising new class of anticancer drugs.
  • The development of these agents enhances basic research into Bcl-2-mediated apoptosis.
  • Targeting the Bcl-2 family opens new therapeutic strategies for cancer treatment.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...